French fries that work like Ozempic: The push to make medicine you can eat
'Those seeds are tiny, the size of a pinhead, so they're never going to be enough to be therapeutic. But we'd be interested in putting it into something bigger … peanuts or chickpeas.'
Craik's team has also crafted cherry tomatoes that contain a cyclopeptide going through clinical trials in Sweden as an experimental treatment for multiple sclerosis symptoms.
It's very hard for a new drug to make it through the clinical trial process, and many promising candidates falter. But if the peptide proves effective, Craik can imagine people with multiple sclerosis eating a Greek salad or sipping a Bloody Mary made with the tomatoes and feeling their symptoms ease.
The ARC grant and partnership will also explore a cholesterol-reducing drug that could be spliced into vegetables, as well as a peptide that targets an appetite receptor and induces fullness. Craik said it could serve as an alternative to Ozempic.
Loading
'My dream would be to put that into potatoes so that you could have your McDonald's French fries and not worry about obesity.'
These products, at this stage, are hypothetical. One of the research goals is to have a food product ready for trials by the end of the three-year grant.
It's also unclear which regulatory jurisdiction the products would fall under. Whether they're considered nutraceuticals, medicines, or genetically modified foods will dictate which bodies need to be involved before they're grown and sold commercially, such as the Office of the Gene Technology Regulator.
'We're hoping, to start with, that they will fall under a nutraceutical, where it's a very light dose, and you'd have to eat tonnes of product to get anywhere dangerous,' said Phyllome chief executive Sebastien Eckersley-Maslin.
Phyllome grows packaged vegetables such as spinach and rocket in automated 'plant factories'. Robots whizz around the indoor vertical farm in inner Sydney's Alexandria and take a photo of plants every hour, analysing the crops with AI, and harvest them when they're ready.
'In essence, our entire farm here has zero human interaction, from sowing through to picking bags off the back of a packager,' Eckersley-Maslin said. 'Everything in the middle is automated by robots.'
The partnership will first focus on growing peptides aimed at pain relief, cholesterol management and appetite suppression in the native tobacco plant Nicotiana benthamiana.
The tobacco plants can't be eaten, but work as natural 'bio-factories' to produce the target peptides, which can be extracted from the plant's leaves.
Loading
The plants were discovered near Wolf Creek in Western Australia, of Hollywood horror fame, and proved useful because they have weak immune systems, which makes it easier to insert the genes that code for the production of cyclotides.
The next stage of the research will work on making the same genetic tweaks in plants that produce food.
Said Craik: 'It's sort of, if you like, going back 3000 years to Hippocrates, who said, 'Let food be thy medicine'.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

AU Financial Review
a day ago
- AU Financial Review
How Ozempic's maker lost the weight loss fight
Until a year ago, Danish drugmaker Novo Nordisk was riding high. It had been first to market with an injectable diabetes treatment and the name Ozempic quickly became shorthand for new class of blockbuster weight loss drugs. But competition started to catch up, a new drug trial disappointed, shares and growth fell and its chief executive departed in May. Then this week a major profit warning knocked more than €60 billion ($106 billion) off its value. The company also announced that senior executive Maziar Mike Doustdar would become the new CEO.

Sydney Morning Herald
3 days ago
- Sydney Morning Herald
Ozempic drugmaker just became a victim of its own success
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.

The Age
3 days ago
- The Age
Ozempic drugmaker just became a victim of its own success
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.